For research use only. Not for therapeutic Use.
Trilexium (Cat No.: I040073) is a novel, research-grade compound with potential applications in neurological disease, cancer, and inflammation research. Designed for high specificity and potency, it modulates key signaling pathways involved in cell proliferation, immune response, and neurodegeneration. With excellent bioavailability and selectivity, Trilexium is ideal for in vitro and in vivo studies, supporting drug discovery and mechanistic research. Its optimized structure enhances stability and efficacy, making it a valuable tool for exploring innovative therapeutic strategies in precision medicine and targeted therapies.
| CAS Number | 1983180-82-0 |
| Synonyms | (3R,4S)-4-(3-fluoro-4-hydroxyphenyl)-3-(4-hydroxy-3,5-dimethoxyphenyl)-8-methyl-3,4-dihydro-2H-chromen-7-ol |
| Molecular Formula | C24H23FO6 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H23FO6/c1-12-18(26)7-5-15-22(13-4-6-19(27)17(25)8-13)16(11-31-24(12)15)14-9-20(29-2)23(28)21(10-14)30-3/h4-10,16,22,26-28H,11H2,1-3H3/t16-,22-/m0/s1 |
| InChIKey | RDQGRFVVYZSNMO-AOMKIAJQSA-N |
| SMILES | CC1=C(C=CC2=C1OCC(C2C3=CC(=C(C=C3)O)F)C4=CC(=C(C(=C4)OC)O)OC)O |
| Reference | [1]. Stevenson AJ, et al. Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo. Sci Rep. 2018 Mar 23;8(1):5144. [2]. Ehteda A, et al. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas. Mol Cancer Ther. 2023 Dec 1;22(12):1413-1421. |
